research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
=== August === August 1 A mass shooting occurs at an In-N-Out in Twin Falls, Idaho, leaving four dead (including the perpetrator) and seven injured. The Marine Corps reports that an F-35B stealth warplane crashed in California, but the pilot bailed safely. Cyberwarfare during the Iran war: The New York Times reports, citing state and local officials, that evidence leads to Iran in a series of cyberattacks against water systems in at least seven US states, with Michigan being the second state to report the attacks publicly. August 2 – 2026 Iran war: Following Qatari diplomatic efforts to avert planned strikes and reopen the Strait of Hormuz, and concerns raised by Saudi Crown Prince Mohammed bin Salman over the proposed operation, Trump says that the United States and Israel have called off an attack on Iran after Tehran requested additional time to reach an agreement. Trump nevertheless stresses that the United States remains prepared to launch a large-scale bombing campaign against Iran. August 3 – The Supreme Court declines to halt a $655 million judgement against Palestinian authorities for attacks that killed and maimed Americans in Israel from 2002 to 2004. August 4 – The Women's National Basketball Association (WNBA) announces that the expansion team in Cleveland, Ohio, will be called the Sirens. The organization will debut in 2028. August 5 Drive-thru chain Salad and Go files for Chapter 11 bankruptcy and closes all 70 of its locations across Arizona and Nevada, citing the 2026 cyclosporiasis outbreak as part of the reason for declining business.
The francium atoms leave the gold target as ions, which are neutralized by collision with yttrium and then isolated in a magneto-optical trap (MOT) in a gaseous unconsolidated state. Although the atoms only remain in the trap for about 30 seconds before escaping or undergoing nuclear decay, the process supplies a continual stream of fresh atoms. The result is a steady state containing a fairly constant number of atoms for a much longer time. The original apparatus could trap up to a few thousand atoms, while a later improved design could trap over 300,000 at a time. Sensitive measurements of the light emitted and absorbed by the trapped atoms provided the first experimental results on various transitions between atomic energy levels in francium. Initial measurements show very good agreement between experimental values and calculations based on quantum theory. The research project using this production method relocated to TRIUMF in 2012, where over 106 francium atoms have been held at a time, including large amounts of 209Fr in addition to 207Fr and 221Fr. Other synthesis methods include bombarding radium with neutrons, and bombarding thorium with protons, deuterons, or helium ions. 223Fr can also be isolated from samples of its parent 227Ac, the francium being milked via elution with NH4Cl–CrO3 from an actinium-containing cation exchanger and purified by passing the solution through a silicon dioxide compound loaded with barium sulfate.
Garcia believed metformin to have bacteriostatic, antiviral, antimalarial, antipyretic, and analgesic actions. In a series of articles in 1954, Polish pharmacologist Janusz Supniewski was unable to confirm most of these effects, including lowered blood sugar. Instead, he observed antiviral effects in humans. French diabetologist Jean Sterne studied the antihyperglycemic properties of galegine, an alkaloid isolated from G. officinalis, which is related in structure to metformin, and had seen brief use as an antidiabetic before the synthalins were developed. Later, working at Laboratoires Aron in Paris, he was prompted by Garcia's report to reinvestigate the blood sugar-lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" (glucose eater) for the medication and published his results in 1957. It was introduced as a medication in France in 1957. Metformin became available in the British National Formulary in 1958. It was sold in the UK by a small Aron subsidiary called Rona. Broad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s. Metformin was approved in Canada in 1972, but did not receive approval by the U.S. Food and Drug Administration (FDA) for type 2 diabetes until 1994. Produced under license by Bristol-Myers Squibb, Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995. Generic formulations are available in several countries.
Sources: en.wikipedia.org
In September 2014, Creative Business House along with Donnons Leur Une Chance, created the International Dwarf Fashion Show to raise awareness and boost self-confidence of people living with dwarfism. A number of reality television series on Lifetime, beginning with Little Women: LA in 2014, focused on showing the lives of women living with dwarfism in various cities around the United States.
== Selected publications == Yang, Yee Hwa; Speed, Terry (2002), "Design issues for cDNA microarray experiments", Nature Reviews Genetics, 3 (8): 579–588, doi:10.1038/nrg863, PMID 12154381, S2CID 260480 Dudoit, Sandrine; Yang, Yee Hwa; Callow, Matthew J.; Speed, Terence P. (2002), "Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments", Statistica Sinica, 12 (1): 111–139, JSTOR 24307038, MR 1894191 Yang, Yee Hwa; Dudoit, Sandrine; Luu, Percy; Lin, David M.; Peng, Vivian; Ngai, John; Speed, Terence P. (2002), "Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation", Nucleic Acids Research, 30 (4): e15, doi:10.1093/nar/30.4.e15, PMC 100354, PMID 11842121 Gentleman, Robert C.; Carey, Vincent J.; Bates, Douglas M.; Bolstad, Ben; Dettling, Marcel; Dudoit, Sandrine; Ellis, Byron; Gautier, Laurent; Ge, Yongchao; Gentry, Jeff; Hornik, Kurt; Hothorn, Torsten; Huber, Wolfgang; Iacus, Stefano; Irizarry, Rafael; Leisch, Friedrich; Li, Cheng; Maechler, Martin; Rossini, Anthony J.; Sawitzki, Gunther; Smith, Colin; Smyth, Gordon; Tierney, Luke; Yang, Jean Y. H.; Zhang, Jianhua (2004), "Bioconductor: open software development for computational biology and bioinformatics", Genome Biology, 5 (10): R80, doi:10.1186/gb-2004-5-10-r80, PMC 545600, PMID 15461798
Pichet Chuamuangpan of Pheu Thai was disqualified by the Constitutional Court for misusing funds on 1 August. His seat, Chiang Rai 7th district, continued to be held by Pheu Thai after Sa-nga Prommuang won the by-election on 14 September. On 28 September, Bhumjaithai candidate Chintawan Traisaranakul won Sisaket 5th district from Pheu Thai following the death of MP Amornthep Sommai in June 2025. Bhumjaithai won another seat from Pheu Thai in the by-election for Kanchanaburi 4th district on 19 October. Wisuda Vicheansil won the seat following the resignation of his father Sakda Vicheansil to join Bhumjaithai. On 7 September, Pheu Thai party-list MP Noppadon Pattama resigned.
Sources: en.wikipedia.org
There are 20 known isotopes of fermium, with atomic weights of 241 to 260, of which 257Fm is the longest-lived with a half-life of 100.5 days. Other isotopes are considerably shorter: 253Fm has a half-life of 3 days, 252Fm of 25.4 h, 255Fm of 20.1 h, while 251Fm of 5.3 h, 254Fm of 3.2 h, and 256Fm of 2.67 hours. All the remaining ones have half-lives ranging from 30 minutes to less than a millisecond. The neutron capture product of fermium-257, 258Fm, undergoes spontaneous fission with a half-life of just 370(14) microseconds; 259Fm and 260Fm also undergo spontaneous fission (t1/2 = 1.5(3) s and 4 ms respectively). This means that neutron capture does not create nuclides with a mass number greater than 257, unless carried out at extremely high flux, as in a nuclear explosion (or the astrophysical r-process), since no accessible fermium isotopes undergo beta minus decay to the next element, mendelevium. Because of this impediment in forming heavier isotopes, these short-lived isotopes 258–260Fm constitute the "fermium gap." Deliberate attempts at nuclear explosion synthesis, however, also failed to create heavier nuclei, and as a result were deemed not worth continuing.
11 December – Researchers demonstrate the use of biological-electronic hybrid Organoid Intelligence, 'Brainoware' (see 1 March), for speech recognition. 12 December – Asteroid 319 Leona occults the bright star Betelgeuse for about 12 seconds as viewed on a narrow path from China to Mexico. 13 December Scientists report that the contents of the sample-return mission of the OSIRIS-REx mission to asteroid Bennu revealed organic molecules as well as unknown materials which require more study to have a better idea of their composition and makeup. The smallest known brown dwarf, weighing just three to four times the mass of Jupiter, is discovered in star cluster IC 348 by astronomers using the James Webb Space Telescope.
== Further reading == Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, et al. (February 2022). "Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency". Molecular Therapy. 30 (2): 509–518. doi:10.1016/j.ymthe.2021.11.005. PMC 8822132. PMID 34763085.{{cite journal}}: CS1 maint: overridden setting (link)
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.